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Ivanics et al.

The Toronto Postliver Transplantation
Hepatocellular Carcinoma Recurrence
Calculator: A Machine Learning
Approach

Tommy Ivanics ,1,2,3,* Walter Nelson,4,5,* Madhukar S. Patel,6 Marco P.A.W. Claasen,1,7
Lawrence Lau,1 Andre Gorgen,1 Phillipe Abreu,1 Anna Goldenberg,8 Lauren Erdman,8,9,** and
Gonzalo Sapisochin1,10,**
1 Multi-Organ Transplant Program, Division of General Surgery, Toronto General Hospital, University Health Network, University
of Toronto, Toronto, ON, Canada; 2 Department of Surgery, Henry Ford Hospital, Detroit, MI; 3 Department of Surgical
Sciences, Uppsala University, Akademiska Sjukhuset, Uppsala, Sweden; 4 Centre for Data Science and Digital Health, Hamilton
Health Sciences, Hamilton, ON, Canada; 5 Department of Statistical Sciences, University of Toronto, Toronto, ON, Canada;
6 Division of Surgical Transplantation, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX;
7 Department of Surgery, Erasmus MC, University Medical Center Rotterdam, the Netherlands; 8 Centre for Computational
Medicine, SickKids Research Institute, University of Toronto, Toronto, ON, Canada; 9 Center for Computational Medicine, SickKids
Research Institute, Toronto, ON, Canada; and 10 Abdominal Transplant & HPB Surgical Oncology, Toronto General Hospital,
University of Toronto, Toronto, ON, Canada

Liver transplantation (LT) listing criteria for hepatocellular carcinoma (HCC) remain controversial. To optimize the utility of
limited donor organs, this study aims to leverage machine learning to develop an accurate posttransplantation HCC recurrence
prediction calculator. Patients with HCC listed for LT from 2000 to 2016 were identified, with 739 patients who underwent
LT used for modeling. Data included serial imaging, alpha-fetoprotein (AFP), locoregional therapies, treatment response,
and posttransplantation outcomes. We compared the CoxNet (regularized Cox regression), survival random forest, survival
support vector machine, and DeepSurv machine learning algorithms via the mean cross-validated concordance index. We
validated the selected CoxNet model by comparing it with other currently available recurrence risk algorithms on a held-out
test set (AFP, Model of Recurrence After Liver Transplant [MORAL], and Hazard Associated with liver Transplantation
for Hepatocellular Carcinoma [HALT-HCC score]). The developed CoxNet-based recurrence prediction model showed a
satisfying overall concordance score of 0.75 (95% confidence interval [CI], 0.64-0.84). In comparison, the recalibrated risk
algorithms’ concordance scores were as follows: AFP score 0.64 (outperformed by the CoxNet model, 1-sided 95% CI, >0.01;
P = 0.04) and MORAL score 0.64 (outperformed by the CoxNet model 1-sided 95% CI, >0.02; P = 0.03). The recalibrated
HALT-HCC score performed well with a concordance of 0.72 (95% CI, 0.63-0.81) and was not significantly outperformed
(1-sided 95% CI, ≥0.05; P = 0.29). Developing a comprehensive posttransplantation HCC recurrence risk calculator using
machine learning is feasible and can yield higher accuracy than other available risk scores. Further research is needed to confirm the utility of machine learning in this setting.

Liver Transplantation 0 1‒10 2021 AASLD.

Received May 26, 2021; accepted September 23, 2021.

Liver transplantation (LT) is the best treatment option
for patients with early stages of hepatocellular carcinoma (HCC).(1-4) However, the use of LT depends on
Abbreviations: AFP, alpha-fetoprotein; BMI, body mass index; CI,
confidence interval; ETOH, Alcohol; HALT-HCC, Hazard Associated
with Liver Transplantation for Hepatoceullar Carcinoma; HBV,
hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis

maintaining a balance between patient-specific survival benefit, the availability of alternative treatment
modalities,(5,6) and the equitable distribution of donor
organs.(5,7-12)
Current selection criteria aim to avoid transplantation futility by excluding patients at a high risk of
tumor recurrence.(10,11) Selecting patients with HCC
within Milan criteria has been shown to provide
excellent patient outcomes.(13-15) However, the Milan
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criteria has been challenged by other series reporting
equivalent outcomes for transplanted patients with
larger and more numerous tumors. Furthermore, while
the use of parameters such as tumor size and number simplify the criteria,(14,16,17) recent studies have
shown that the sole reliance on morphologic features
does not adequately reflect tumor biology.(18,19) Thus,
the need to incorporate additional prognostic factors,
such as serum alpha-fetoprotein (AFP score)(20-22) and
neutrophil-to-lymphocyte ratio (Model of Recurrence
After Liver Transplant [MORAL] score),(23) became
apparent and was further explored. In addition, radiologic and AFP responses to downstaging or bridging
treatment have also been suggested to be important in
predicting outcomes after LT.(24-26)
Given the opportunity cost of suboptimal organ
allocation, creating a more precise and quantitative
C virus; IQR, interquartile range; LASSO, least absolute shrinkage
and selection operator; LT, liver transplantation; MELD, Model for
End-Stage Liver Disease; MELD–Na, Model for End-Stage Liver
Disease–sodium; MLA, Machine learning algorithm; MORAL,
Model of Recurrence After Liver Transplant; mRECIST, modified
Response Evaluation Criteria In Solid Tumors; NASH, nonalcoholic
steatohepatitis; NLR, Neutrophil-lymphocyte ratio; SRTR, Scientific
Registry of Transplant Recipients.

posttransplantation outcome calculator remains paramount. However, one of the main hurdles in developing such a calculator has been the limitation of standard
statistical methods to account for many variables and
their potential for various interactions. Looking forward,
the amount of clinical data is only likely to increase.
Machine learning represents a tool that can be used to
derive meaning from such data.(27) Traditionally, humans
have analyzed data and adapted systems to the changes
in data patterns. However, as the volume of data surpasses the ability of humans to interpret and write rules,
there will likely be a natural inclination to increasingly
turn to automated systems that can actively learn from
the data and adapt to shifting landscapes. With progress
in applying machine learning techniques in medicine, we
propose that these methods can be utilized to identify
complex nonlinear relationships between a comprehensive set of factors and recipient outcomes in transplantation oncology.(28-31) Thus, we hypothesize that an
accurate posttransplantation HCC recurrence calculator
can be developed using a machine learning algorithm
mapped on preoperative patient and tumor characteristics and have designed this study as a proof of concept.

Methods

Address reprint requests to Gonzalo Sapisochin, M.D., Ph.D., M.Sc.,
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Patients who underwent LT for HCC from 2000 to
2016 were identified from the prospectively maintained
Toronto General Hospital LT database. A detailed
description of listing criteria has been outlined elsewhere.(19) Moreover, in contrast to the United States,
there is no mandatory 6-month waiting time for patients
with HCC exception points. In Ontario specifically, patients with HCC that meet selection criteria for listing
start at 22 points (Model for End-Stage Liver Disease
[MELD]) and increase by 3 points every 3 months.(32)
Recipients with incidentally discovered HCC in the
explanted liver were excluded. Data on age, sex, body
mass index, comorbidities, etiology of liver disease, and
MELD score were collected. HCC-specific variables
were tumor size, volume, number, and AFP levels, all at
transplantation, listing, and delisting (dropout). Bridging
therapy (administered or not), the timing of bridging
therapy, and number of sessions were also included.

Liver Transplantation, Vol. 0, No. 0, 2021Ivanics et al.

DEVELOPING A MACHINE
LEARNING MODEL

A machine learning approach was used to create a
model to determine the risk of posttransplantation
HCC recurrence. Nearly 15% of randomly selected patients were held out as a test set. The remaining 85% of
patients constituted the development set. This splitting
ratio was chosen based on a classic rule of prescribing an
80%:20% split between the development and test sets,
with an increased training set size of 85% to account for
the rate of right censorship in the recurrence outcome.
The candidate machine learning models were
selected on the basis of being representative of the main
paradigms of machine learning: regularized regression,
ensembled decision trees, support vector machines,
and deep neural networks. CoxNet refers to the usual
Cox proportional hazards model, with an added penalty term that regularizes the coefficients during model
fitting. This penalty term has the effect of driving coefficients with little or no independent predictive value to
0 and shrinking other coefficients to prevent overfitting.
Random survival forests are a generalization of decision
trees. Whereas the output of a traditional decision tree is
a probability or binary decision, the output of a survival
tree is a valid cumulative hazard function. A survival
random forest consists of a large number of these trees
with the final prediction of the forest being the mean
prediction from each individual tree. Survival support
vector machines project data into high-dimensional
space using a patient-patient similarity function defined
over the predictors. The model then learns to rank the
training samples; new samples are then ranked relative
to the training samples. Lastly, DeepSurv is an alternative to the Cox proportional hazards model where the
relative risk term is parameterized by an artificial neural
network instead of linear regression, enabling the application of deep learning. Within the development set,
the 4 machine learning algorithms were compared by
5-fold cross-validation to identify the best performing
algorithm to develop the final model (Supporting Fig. 1
and Supporting Table 1). The number of folds was
chosen to ensure sufficient data in each fold for model
selection in each iteration of cross-validation. Of note,
all the models other than CoxNet investigated for the
presence of nonlinear interactions in the set of available
pre-LT variables. The mean concordance for each algorithm for the optimal set of hyperparameters across the
held-out folds during the cross-validation step (only on
the development set) was reported to assess each model’s

TABLE 1. Our Model’s Coefficients (Development Set)
Variable

Coefficient

Hazard
Ratio

Age

−0.004

0.996

0.228

1.257

−0.153

0.858

Total tumor diameter (at listing)

0.041

1.042

Largest lesion size (at listing)

0.020

1.021

log-AFP (before transplantation)

0.191

1.210

Largest lesion size (before transplantation)

0.020

1.020

−0.060

0.942

0.025

1.025

−0.010
0.038

0.990
1.039

Number of bridging therapies
Etiology: other

Within Milan criteria (before
transplantation)
Neutrophil count (before transplantation)
Sodium (before transplantation)
Tumor burden score (before
transplantation)

NOTE: The model was fit to a standardized predictor matrix, that
is, the mean and standard deviation were subtracted prior to model
fitting. However, these coefficients have been rescaled according
to the standard deviation to ensure that the hazard ratios are interpretable with respect to the original units (with the exception of
log-AFP, which must still be interpreted on the natural log-scale).
y = (age × 0.23) + (etiology other × −0.15) + (total tumor diameter × 0.04) + (largest lesion size [at listing] × 0.02) +
(log-AFP*0.19) + (largest lesion size lesion [before
LT] × 0.02) + (within Milan criteria [before LT] × −0.06) + (neutrophil count [before LT] × 0.02) + (sodium [before
LT] × −0.01) + (tumor burden score [before LT] × 0.04)
Age: per 1-year increase
Etiology: other (reference non-other)
Total tumor diameter: per 1-cm increase
Largest lesion size (at listing): per 1-cm increase
AFP: per 1-unit increase (ng/mL)
Largest lesion size (before LT): per 1-cm increase
Within Milan criteria (before LT): reference not within Milan criteria before LT
Neutrophil count (before LT): per 1-unit increase (×109/L)
Sodium (before LT): per 1-unit increase (mmol/L)
Tumor burden score (before LT): per 1-unit increase.

performance. The best performing model, according to
the concordance index, was trained on the full development set with the optimal set of hyperparameters, of
which all non-zero coefficients are reported in Table 1.
This was referred to as the final model.

COMPARISON WITH PREVIOUSLY
PUBLISHED MODELS

We compared the final performing machine learning
model (CoxNet) with the models underlying several
other HCC recurrence scores: MORAL,(23) AFP,(33)
and Hazard Associated with Liver Transplantation for
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TABLE 2. Coefficient Comparison
Reported
Coefficient

Refitted
Coefficient

Maximum AFP ≥200 (before
transplantation)

0.318

0.483

Neutrophil-to-lymphocyte ratio ≥5 (before
transplantation)

0.417

0.063

Maximum lesion size ≥3 cm (before
transplantation)

0.265

0.454

Variable/Condition
a. MORAL model

b. AFP model
Maximum lesion size ≤3 cm (at listing)

—

—

3 cm < maximum lesion size ≤6 cm (at
listing)

0.069

0.111

Maximum lesion size >6 cm (at listing)

0.343

0.356

Lesion count ≤3 (at listing)

—

—

Lesion count ≥4 (at listing)

0.177

0.157

—

—

100 < AFP ≤ 1000 (at listing)

0.170

0.097

AFP >1000 (at listing)

0.241

0.279

Tumor Burden Score (before
transplantation)

0.376

0.363

log-AFP (before transplantation)
MELD-Na score (before transplantation)

0.547
0.077

0.609
−0.028

AFP ≤100 (at listing)

c. HALT-HCC model

NOTE: All coefficients for each model were normalized such that
their absolute values sum to one, to account for potential scale differences when comparing the between columns. Directional discrepancies are underlined. AFP units is in ng/mL. All coefficients
for each model were normalized such that their absolute values sum
to 1, to account for potential scale differences when comparing the
between columns. Directional discrepancies are underlined.

Hepatoceullar Carcinoma (HALT-HCC).(34) These
models were selected because they use pre-LT variables and evaluated a similar outcome (recurrence)
which allowed for appropriate comparisons to be performed. The AFP model and the MORAL score are
well-known prognostic scores used to predict HCC
recurrence following LT.(15,33) The AFP model aims
to identify HCC candidates with a low recurrence risk
who would otherwise be excluded based on the Milan
criteria. It also takes into account the largest tumor
diameter, number of nodules, and the AFP level.(22)
The pretransplantation MORAL score (pre-MORAL
[herein referred to as MORAL score]) uses preoperative neutrophil-to-lymphocyte ratio, AFP, and the
maximum tumor size to predict post-LT recurrence.
The AFP variables at listing and delisting were log-
transformed to satisfy the assumption of normally
distributed residuals. The Tumor Burden Score,(35) an
input to the HALT-HCC model, was derived and used
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as an engineered predictor to the machine learning
models for fairness. For each comparison algorithm,
the corresponding Cox model was recalibrated on our
development set and evaluated on the held-out test set.
As expected, this improved the resulting concordance
statistics on the held-out test set for each of the comparison models. In Table 2, we report the differences
between the coefficients reported in each comparison
model’s original publication and the coefficients found
by recalibrating the Cox model on our development
set. Lastly, we assessed, both before and after recalibration, whether CoxNet offered advantages over the
other models by testing for improvement in model performance according to the concordance index.

FOLLOW-UP AND RECURRENCE
DEFINITION

Following transplantation, patients were followed with
either contrast-enhanced computed tomography of
the chest and abdomen or ultrasound together with
AFP measurements in 3-month intervals for the first
2 years. After that, surveillance occurs every 6 months
for 2 years and then yearly. Additional imaging studies were performed for any suspected recurrence, including contrast-enhanced computed tomography,
contrast-enhanced ultrasound, or magnetic resonance
imaging.(36) The time to recurrence was calculated
from transplantation to the first imaging study that
confirmed tumor recurrence.

DATA ANALYSIS

Continuous variables were described using median and
interquartile range (IQR), whereas categorical variables
were described using frequency and percentage (%).
Disease-free, intention-to-treat, and posttransplantation survival were evaluated using the Kaplan-Meier
method in R (R Core Team).(37) All models were fit using
the scikit-survival package in Python 3.6.(38) The grid
search space for each model is given in the Supporting
Material. All P values were computed via bootstrapping
(the baseline procedure described by Kang et al.(39)), except where expressly noted. Two-sided z-tests were used
in our initial models (CoxNet, survival random forest,
survival support vector machine, and DeepSurv) to test
the alternative hypothesis of differences in model performance. One-sided z-tests were used to compare our
best model with 3 competing models in order to test the
alternative hypothesis that our model performs better
than previously published algorithms.

Liver Transplantation, Vol. 0, No. 0, 2021Ivanics et al.

Results

The study data set comprised 1013 patients with
HCC listed for LT. Of these, 831 (82%) were male,
and the most common cause of underlying liver disease was chronic hepatitis C (51.7%). At listing, 304
(30%) patients were beyond Milan criteria. Of the
listed patients, 739 (73.0%) underwent LT, of which
142 (19.2%) had grafts from a living donor. While
on the waiting list, 625 (61.7%) underwent bridging treatment, with 241 (38.6%) having more than 1
treatment. Of a total of 977 bridging therapy treatments, the majority received either radiofrequency
ablation (564 treatments [57.7%]) or transarterial
chemoembolization (311 treatments [31.8%]). The
median time on the waiting list was 6.1 months
(IQR, 3.0-10.3). During the wait time, 269 (26.6%)
patients dropped out and 5 had not experienced an
event (dropout or transplantation) by the end of the
study follow-up. Baseline patient characteristics are
summarized in Table 3.
Among the patients who underwent LT, 143
(19.4%) had tumor recurrence after a median follow-up of 4.5 years (IQR, 2.0-8.9). The 1-, 3-, and
5-year disease-free survival rates were 91.5%, 82.4%,
and 79.9%, respectively (Fig. 1A). Most recurrences
(79%) occurred in the first 3 years after LT, as demonstrated by Fig. 2. The median intention-to-treat overall survival was 3.4 years (IQR, 1.5-7.4). The 1-, 3-,
and 5-year intention-to-treat overall survival rates
were 83.3%, 63.8%, and 55.5%, respectively (Fig. 1B).
When using these data to fit CoxNet, survival
random forest, survival support vector machine,
and DeepSurv models, CoxNet performed the best
according to cross-validation within the development
set (Supporting Table 1), although this was not statistically significant. The characteristics of the derivation and test cohorts are provided in Supporting
Table 2. Based on both model performance and parsimony, CoxNet was selected as the final model, and
trained on the full development set. The CoxNet
model being the best performing model also signified
that nonlinear interactions were not included. The
selected optimal hyperparameters include an L1-ratio
of 0.55 (commonly referred to in the elastic net literature as α), suggesting that the benefit of CoxNet
is its ability to both automatically exclude meaningless predictors via L1-regularization and reduce the
contributions of less meaningful predictors via L2-
regularization. The inclusion of particular variables is

TABLE 3. Patients Baseline Characteristics
Total (n = 1013)

Variable
Male sex, n (%)

831 (82.0)

Age (years), median (IQR)

59 (53.6-63.7)

BMI (kg/m2), median (IQR)

26.9 (24.2-30.4)

MELD score at listing, median (IQR)

10 (8-14)

AFP level at listing (ng/mL), median (IQR)

11 (5-45)

Etiology, n (%)
HCV

524 (51.7)

HBV

204 (20.1)

ETOH

138 (13.6)

NASH

67 (6.6)

Other

80 (7.9)

Months on waiting list, median (IQR)

6.1 (3.0-10.3)

Median tumor size at listing (cm), median (IQR)

2.8 (1.9-3.9)

Tumor number at listing, median (IQR)

1 (1-2)

Within Milan criteria at listing, n (%)

709 (70.0)

Bridging therapy (yes), n (%)

625 (61.7)

Number of bridging therapies, n (%)
0

388 (38.3)

1

384 (37.9)

2

156 (15.4)

3

64 (6.3)

4

19 (1.9)

5

2 (0.2)

Dropout rate while on waiting list, n (%)
Median tumor size before LT (cm), median (IQR)
Tumor number before LT, median (IQR)

269 (26.6)
1.6 (0.0-3.0)
1 (0-2)

Within Milan criteria before LT, n (%)

580 (78.5)

Transplanted, n (%)

739 (73.0)

Living donor liver graft, n (%)

142 (19.2)

Milan on pathology, n (%)
Median tumor size on pathology (cm), median
(IQR)
Tumor number on pathology, median (IQR)

368 (49.9)
3.0 (2.0-4.0)
5 (3-8)

Tumor differentiation, n (%)
Well

89 (14.5)

Moderate

457 (74.3)

Poor

69 (11.2)

Unable to be assessed/missing
Microvascular invasion (yes), n (%)
Follow-up of transplanted patients (years), median
(IQR)
Recurrence rate, n (%)

124
207 (28.0)
4.5 (2.0-8.9)
143 (19.4)

always determined by their contribution to predictive
performance, rather than their individual statistical
significance—a fundamental difference between the
regularization-based and forward selection–based
approaches, respectively.
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FIG. 1. (A) Posttransplantation disease-free survival. (B) Intention-to-treat overall survival.

Within the held-out test set, we next assessed whether
our CoxNet model outperformed the AFP, MORAL,
and HALT-HCC scores, using the coefficients given
in their original publications. Indeed, our final model,
with a concordance of 0.75, outperformed the MORAL
score, with a concordance of 0.62 and a difference of 0.13
(1-sided 95% confidence interval [CI], >0.04; P = 0.01);
the AFP score, with a concordance of 0.63 and a difference of 0.12 (1-sided 95% CI, >0.03; P = 0.02); and
the HALT-HCC score, with a concordance of 0.64 and
a difference of 0.10 (1-sided 95% CI, >0.03; P = 0.02).
Lastly, the conventional models were recalibrated on
the development set used to train our machine learning
model, and we subsequently assessed whether the gain
in performance of the machine learning approach holds
over the recalibrated models. The recalibrated MORAL
score, with a concordance of 0.64, continued to be outperformed by the CoxNet model (1-sided 95% CI,
>0.02; P = 0.03). Similarly, the recalibrated AFP score,
with a concordance of 0.64, was outperformed by our
model (1-sided 95% CI, >0.01; P = 0.04). However, the
recalibrated HALT-HCC score performed well (with a
concordance of 0.72) and was not significantly outperformed (1-sided 95% CI, ≥0.048; P = 0.29).
As the final model is linear, its coefficients (Table 1)
can be interpreted as in other Cox models. In particular,
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the risk score can be computed by multiplying the coefficient for each variable with its value and summing up
the products. In addition, the final machine learning
model is available as an online calculator at https://
hcccalculator.ccm.sickkids.ca.

Discussion

This study aimed to develop an accurate posttransplantation HCC recurrence calculator using available
clinicopathologic data. A machine learning approach
was used due to the vast number of potentially predictive factors and the possibility of multiple nonlinear
interactions. Our results demonstrate the feasibility of
applying machine learning in transplantation oncology
and suggest that this risk prediction method provides
improved accuracy over other currently available risk
scores, including AFP and MORAL.
Four well-known supervised learning algorithms
were developed in this study, with the CoxNet model
selected based on model performance and parsimony. To assess this new Toronto HCC recurrence
calculator’s validity, its performance was compared
with 3 well-known prognostic calculators—the AFP
model,(33) the MORAL score,(40) and HALT-HCC

Liver Transplantation, Vol. 0, No. 0, 2021Ivanics et al.

algorithm (MLA) model and the HALT-HCC should
thus be done in an external patient cohort. In other
words, a cohort that does not contain any patients used
to derive the HALT-HCC or patients from Toronto.
Notwithstanding this, this model development aimed
not necessarily to outperform currently available models
per se, but rather to evaluate the feasibility of MLA as a
proof-of-concept study and shed light on various techniques and potential pitfalls in the process. By statistically appraising all variables in the data set, potentially
informative features were integrated without additional
selection bias. Notably, the critical variable selection
step sifted out poorly predictive or collinear variables,
limiting noise and over-fitting, and in this way worked
to optimize the model.
Although our model exhibited strong predictive
performance using internal data, external validation
is required before the model can be more broadly
applied.(42) Within this context, given that many transplantation centers restrict listing to patients that meet
the Milan criteria, it is unclear how well the present
model
would perform in that setting, especially given
FIG. 2. Distribution of recurrences over time (months).
that the present cohort included a higher proportion
of patients that exceeded Milan criteria. In a study
(34)
score.
The coefficients derived for the recalibrated by Schrem et al., a prognostic model developed in
AFP and MORAL models largely resemble those Germany to predict 90-day post-LT mortality based
provided in the original publications. By contrast, the on pretransplantation donor and recipient variables
MELD–sodium (MELD-Na) coefficient derived for could not be validated in a cohort of patients from the
the HALT-HCC score in our data set was direction- United Kingdom.(43) This highlighted the challenge
ally different from the published coefficient, suggesting of suboptimal translation between 2 transplantation
a discrepancy. Notably, the MELD-Na in the HALT- environments with different donor/recipient populaHCC was the only directionally discrepant variable tions, health care systems, allocation policies, and clinacross all 3 comparison models. The improved per- ical/surgical practices. Because of the long-standing
formance of the Toronto HCC recurrence calculator application of the Extended Toronto Criteria,(19) in
may be due, in part, to the methodologic advantages our model, patients were not excluded based on HCC
of the machine learning approach. The HALT-HCC size or number alone, resulting in 30% of the patients
score was generated using a cohort of 420 patients from in the data set falling beyond Milan criteria. This furCleveland Clinic and subsequently validated in a larger ther reflects the ability of the algorithm’s predictive
cohort of US liver recipients from the Scientific Registry performance to be maintained for patients who are
of Transplant Recipients (SRTR), where Cleveland beyond conventional macromorphological transplanClinic patients are included.(34) In the subsequent inter- tation criteria. Further, a prediction model validated
national validation cohort by Firl et al., of the 4089 on internal data alone will likely yield the most optipatients included, 1851 were from North America (of mistic representation of the model. Nonetheless, it
which the US constituents were part of the SRTR data; remains to be determined whether internally derived
460 [45.1%] in the training and 1391 [45.3%] in the prognostic models are required to be generalizable to
validation cohorts, respectively).(41) Given this overlap other settings or whether individual health care sysin patients in the development and subsequent valida- tems should optimize models to serve their specific
tion cohort, it is conceivable that this may have resulted population best.(44,45) Regardless, as this study sugin overly optimistic c-indices. Ideally, a fair assessment gests, incorporating factors reflective of tumor biology,
of the performance of the present machine learning with an emphasis on excellent covariate fidelity and
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granularity, remains an essential tenet in developing a
calculator with high accuracy.
Over the past 2 decades, machine learning algorithms have been increasingly applied for cancer
diagnosis, prognostication, and treatment outcome prediction.(31,42,46,47) Recently, an MLA approach based
on a random forest workflow has been developed by a
group in Germany to predict disease-free survival after
liver resection for HCC.(48) This model had a robust
predictive potential for early recurrence with an area
under the curve of 0.79 (0.66-0.92).(48) In our model,
recurrence was selected rather than recurrence-free
survival (which considers both death and recurrence as
an event), as it may potentially offer greater clinically
relevant insight to refining postoperative management,
given that we censored patients who died from non-
HCC related reasons. As the standard machine learning workflow involves model performance monitoring
and retraining to account for model drift, a multidisciplinary partnership between clinicians and data scientists is required, with a commitment to the curation
and iterative maintenance of data sets to allow for the
development of meaningful decision-support tools.(45)
This process should involve, first and foremost, a
robust, consistent, and objective means of collecting
data. The data may be clinicopathologic characteristics from electronic medical records, genomics, and
imaging studies.(31) Clinicians should strive to establish interdisciplinary partnerships that strive toward a
common goal, rather than a “turf and credit” mindset.
Leveraging the knowledge and technologies of such
partners can achieve synergism. For instance, clinicians help provide a clinically relevant outcome, and
data scientists can identify the optimal methodology to
make predictions for the outcome based on the available data. The HCC recurrence calculator developed
in this study demonstrates the potential for integrating machine learning in transplantation oncology.
Increased accuracy in outcome prediction enables clinicians and patients to make better-informed decisions
regarding their care. In the case of HCC, where LT is
a potentially curative treatment modality, the importance of a quantifiable and accurate recurrence calculator is of particular relevance to ensure fair and equitable
access to the limited number of available donor organs.
This study is limited by its retrospective single-center
study design. Further, the generalizability of the results
requires external validation. Although machine learning results yield high-performance prediction models,
several additional limitations warrant mention. First,
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the quality of the data output is dependent on the
quality of data input. Objective data are thus preferred
over subjective data, such as the modified Response
Evaluation Criteria in Solid Tumors (mRECIST),
which may differ between institutions and radiologists,
for model input, the latter of which is prone to bias. As
a surrogate for response, the size of the largest tumor
size at both listing and before LT were included. The
latter variable captured the size of the viable portion
of the tumor, which was smaller when there was a
successful response to bridging therapy. Although the
variables used in this study were objective, misclassification bias may affect the validity of model performance. Second, despite the high predictive capacity
of machine learning models, there is potential for prediction “overfitting,” which may generate overly optimistic results.(49) This limitation may be overcome by
external validation before algorithms are adopted for
clinical use. Previous non-MLA–based prognostic
scores have included AFP response and found it to be
predictive of outcomes.(24) In the present MLA-based
model, both AFP at listing and AFP before LT were
introduced into the model, but only AFP before LT
remained, as it resulted in improved model predictive
performance. Because AFP response is a linear combination of AFP before transplantation and AFP at listing, all models, including the selected elastic net model,
implicitly consider AFP response. As with other HCC
prognostic calculators, it is important to note that the
time point at which the values of relevant variables are
known dictates the clinical time point when the model
predictions are relevant. For instance, variables known
just before LT are only relevant for patients who can
reach that point and not dropout from the waiting list.
As such, our model, similar to many of the other well-
known HCC prediction models, would be unable to
guide the decision of whether or not to list a patient
for transplantation given that it does not represent an
intention-to-treat analysis of survival but rather than
a per-protocol (from the time of LT) prediction for
recurrence. The utility of this model is therefore primarily to provide a prognostic assessment of oncologic
outcomes from the time of transplantation, which may
potentially help individualize screening for recurrence
or lower thresholds for early institution of future adjuvant therapies/clinical trial inclusion based on predicted
recurrence risk. Future models should also seek to evaluate the prognostic performance of transplantation
outcomes from before or at the time of listing, as this
would potentially help refine current patient selection
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for LT in the treatment of HCC. Lastly, variables from
multiple time points (transplantation listing, bridging
therapy, and transplantation) were incorporated into
this model. This contrasts with de facto data obtained
across multiple institutions in electronic health records
to facilitate billing or patient care, which may lack the
same standardization, completeness, or granularity.(44)
This may, in turn, limit the calculator’s performance in
those settings.(47) Notwithstanding these limitations,
machine learning algorithms represent a powerful
statistical platform that can improve clinical decision
making and, most importantly, patient outcomes.

Conclusion

The development of a posttransplantation HCC
recurrence risk calculator using machine learning is
feasible using a comprehensive data set of relevant
patient and tumor features before LT. This proof-of-
concept study underscores the potential of a machine
learning approach to augment individual clinical decision making and help safeguard equitable organ
allocation.
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